Korean J Ophthalmol.  2015 Dec;29(6):375-381. 10.3341/kjo.2015.29.6.375.

A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery

• Hwang S
• Choi S

• KMID: 2363844
• DOI: http://doi.org/10.3341/kjo.2015.29.6.375

Abstract

PURPOSE
To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery.
METHODS
Between July 2013 and June 2014, we performed surgery using the bare sclera method on 132 eyes (132 patients) with primary pterygium. We randomly selected 33 eyes (33 patients) and treated them with artificial tears four times a day for three months, 29 eyes (29 patients) were treated with topical 0.02% mitomycin C four times a day for five days, 34 eyes (34 patients) were treated with topical 0.05% cyclosporine four times a day for three months, and 36 eyes (36 patients) were treated with topical 2.5% bevacizumab four times a day for three months after surgery. We prospectively determined the recurrence rates of pterygium and complications at the six-month follow-up examination.
RESULTS
At six months after surgery, the recurrence rates in each group were as follows: 45.5% (15 eyes) in the control group, 10.3% (three eyes) in the mitomycin C group, 20.6% (seven eyes) in the cyclosporine group, and 41.7% (15 eyes) in the bevacizumab group (p = 0.004). No serious complications, except subconjunctival hemorrhages, were observed in any group.
CONCLUSIONS
Groups receiving topical 0.02% mitomycin C and 0.05% cyclosporine after surgery showed lower recurrence rates than the control group; however, no difference in recurrence rate was observed between the control group and the group receiving topical 2.5% bevacizumab after surgery.

Keyword

Bevacizumab; Cyclosporine; Mitomycin C; Primary pterygium; Recurrence rates

MeSH Terms

Administration, Topical
Aged
Aged, 80 and over
Alkylating Agents/administration & dosage
Angiogenesis Inhibitors/administration & dosage
Bevacizumab/*administration & dosage
Cell Count
Combined Modality Therapy
Cyclosporine/*administration & dosage
Double-Blind Method
Endothelium, Corneal/pathology
Female
Humans
Immunosuppressive Agents/administration & dosage
Male
Middle Aged
Mitomycin/*administration & dosage
Ophthalmic Solutions
Ophthalmologic Surgical Procedures
Prospective Studies
Pterygium/diagnosis/*drug therapy/*surgery
Recurrence
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Alkylating Agents
Angiogenesis Inhibitors
Bevacizumab
Cyclosporine
Immunosuppressive Agents
Mitomycin
Ophthalmic Solutions
Vascular Endothelial Growth Factor A